A study published in Nature Medicine highlights the effectiveness of a personalized cancer vaccine developed by a Bridge Project team including Bradley Pentelute. Four years after melanoma patients were treated with a personalized vaccine, the resulting immune response remains intact and effective at controlling cancer cells.